1. Medicina utemeljena na dokazima
Kolegij: Istraživanja u biomedicini i zdravstvu III
Seminar 4: Kritička procjena dokaza

2. Što je EBM u praksi? Koraci u medicini utemeljenoj na dokazima
Korak 1: Postavljanje pitanja na koje se MOŽE odgovoriti
Korak 2: Pronalaženje najboljeg dokaza
Korak 3: Brza kritička procjena dokaza
Korak 4: Primjena dokaza
Korak 5: Procjena efektivnosti i efikasnosti procesa

3. 3. Kritička prosudba dokaza
Jesu li rezultati istraživanja valjani?
Kakvi su rezultati?
Mogu li se rezultati primijeniti na konkretnog bolesnika?

4. Primjer: RCT Valjanost istraživanja:
Je li kliničko pitanje jasno definirano?
Je li raspodjela ispitanika u skupine bila slučajna (randomizacija)?
Je li randomizacijski slijed bio poznat liječniku koji prima ispitanike?
Jesu li analizirani svi ispitanici ili je analiza bila prema prethodnom planu (eng. intention to treat)?
Jesu li ispitanici u kontrolnoj i pokusnoj skupini podudarni u odnosu na poznate prognostičke čimbenike?
Jesu li ispitanici/liječnici/ispitivači svjesni kojoj skupini pripadaju?
Je li praćenje ispitanika bilo potpuno?
Jesu li podatci primjereno statistički obrađeni?

5. Primjer: ”Susjeda Vas pita hoće li pastile s cinkom pomoći njezinoj 10-godišnjoj kćeri da lakše preboli prehladu?”
Istraživači navode da je istraživanje randomizirano i na koji je način randomizacija provedena;
Od 124 djece u ispitivanoj skupini, 7 (6%) ih je prekinulo istraživanje, a od 125 djece u kontrolnoj skupini istraživanje je prekinulo troje (2%).
Tijekom analize, obrađeni su svi ispitanici, bez obzira na odustajanje (engl., intention to treat analysis);
Autori navode i podrobno prikazuju parametre koji upućuju na sličnost ispitanika u kontrolnoj i pokusnoj skupini;
Autori također navode da ni djeca niti istraživači koji su davali lijek, nisu znali koji ispitanik što dobiva;
Na kraju, uvjereni ste da je dokazna snaga toga istraživanja dovoljno visoka, i da je mogućnost iskrivljenja rezultata (bias), mala.

6. Primjer: RCT STATISTIKA!!
Rezultat istraživanja: Mjere učinka liječenja
Relativno smanjenje rizika (RRR=relative risk reduction)
Apsolutno smanjenje rizika (ARR=absolute risk reduction)
Broj ispitanika koji je potreban za liječenje (NNT=1/ARR)
95% raspon pouzdanosti (95%CI)
STATISTIKA!!

7. Primjer: ”Susjeda Vas pita hoće li pastile s cinkom pomoći njezinoj 10-godišnjoj kćeri da lakše preboli prehladu?”
Izostanci iz škole
(broj djece koja su izostala)
Smanjenje relativnog rizika (RRR)
Smanjenje apsolutnog rizika (ARR)
Broj ispitanika potreban za liječenje (NNT)
Placebo
CER
Pastile s cinkom
EER
(CER-EER)/CER
CER-EER
1/ARR
20.8%
18.5%
(20.8%-18.5%)/20.8% = 11.1%
20.8% % = 2.3%
1/2.3% = 44 pacijenata
Neželjeni učinci (npr. loš okus u ustima; mučnina; iritacija usta, jezika ili grla; proljev)
Povećanje relativnog rizika (RRI)
Povećanje apsolutnog rizika (ARI)
Broj potreban za neželjeni učinak
(NNH)
1/ARI
79.8%
98.6%
(79.8%-88.6%)/79.8% = 11.0%
79.8% % = 8.8%
1/8.8% = 11 pacijenata

8. Primjer: RCT
Primjenjivost rezultata na konkretnog bolesnika
Jesu li ispitanici u istraživanju slični bolesniku na kojeg želimo primijeniti ispitivani postupak?
Jesu li ispitani svi klinički važni ishodi?
Može li se liječenje provesti u okruženju (engl. setting) u kojemu se bolesnik nalazi?
Postoje li drugi oblici liječenja?
Je li dobit liječenja vrijedna u odnosu na mogući rizik i cijenu?

9. 4. Klinička primjena dokaza
Upute za kliničku praksu
Analiza odlučivanja:
vjerojatnost (probability) x
subjektivna ocjena stanja (utility)
5. Vrjednovanje

10. Što sve treba biti u članku koji opisuje RCT
CONSORT statement
Popis za provjeru
Dijagram toka

11. CONSORT: checklist (25 items)

12. CONSORT: flow diagram

13. CONSORT items and examples Title and abstract
1a Identification as a randomised trial in the title
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)

14. CONSORT items and examples Introduction
Background and objectives
2a Scientific background and explanation of rationale
2b Specific objectives or hypotheses

15. CONSORT items and examples Introduction

16. CONSORT items and examples Methods
Trial design
3a Description of trial design (such as parallel, factorial) including allocation ratio
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons
Participants
4a Eligibility criteria for participants
4b Settings and locations where the data were collected

17. CONSORT items and examples Methods

18. CONSORT items and examples Methods

19. CONSORT items and examples Methods
Interventions
5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
Outcomes
6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
6b Any changes to trial outcomes after the trial commenced, with reasons

20. CONSORT items and examples Methods

21. CONSORT items and examples Methods

22. CONSORT items and examples Methods
Sample size
7a How sample size was determined
7b When applicable, explanation of any interim analyses and stopping guidelines

23. CONSORT items and examples Methods

24. CONSORT items and examples Methods
Randomisation
Sequence generation
8a Method used to generate the random allocation sequence
8b Type of randomisation; details of any restriction (such as blocking and block size)
Allocation concealment mechanism
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

25. CONSORT items and examples Methods

26. CONSORT items and examples Methods

27. CONSORT items and examples Methods
Randomisation
Implementation
10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions
Blinding
11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
11b If relevant, description of the similarity of interventions

28. CONSORT items and examples Methods

29. CONSORT items and examples Methods

30. CONSORT items and examples Methods
Statistical methods
12a Statistical methods used to compare groups for primary and secondary outcomes
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses

31. CONSORT items and examples Methods

32. CONSORT items and examples Methods

33. CONSORT items and examples Results
Participant flow (a diagram is strongly recommended)
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome
13b For each group, losses and exclusions after randomisation, together with reasons
Recruitment
14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped

34. CONSORT items and examples Results

35. CONSORT items and examples Results

36. CONSORT items and examples Results
Baseline data
15 A table showing baseline demographic and clinical characteristics for each group
Numbers analysed
16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

37. CONSORT items and examples Results

38. CONSORT items and examples Results

39. CONSORT items and examples Results
Outcomes and estimation
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended

40. CONSORT items and examples Results

41. CONSORT items and examples Results

42. CONSORT items and examples Results
Ancillary analyses
18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory
Harms
19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms

43. CONSORT items and examples Results

44. CONSORT items and examples Results

45. CONSORT items and examples Discussion
Limitations
20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
Generalisability
21 Generalisability (external validity, applicability) of the trial findings
Interpretation
22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

46. CONSORT items and examples Discussion

47. CONSORT items and examples Discussion

48. CONSORT items and examples Discussion

49. CONSORT items and examples Other information
Registration
23 Registration number and name of trial registry
Protocol
24 Where the full trial protocol can be accessed, if available
Funding
25 Sources of funding and other support (such as supply of drugs), role of funders

50. CONSORT items and examples Other information